A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma
Open Access
- 1 January 2021
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (10) , 2866-2876
Abstract
Background and Aims: The tumor microenvironment can be divided into inflamed, immune-excluded and immune-desert phenotypes according to CD8+ T cell categories with differential programmed cell death protein 1 (PD-L1) expression. The study aims to construct a novel immunotype-based risk stratification model to predict postsurgical survival and adjuvant trans-arterial chemoembolization (TACE) response in patients with hepatocellular carcinoma (HCC).Keywords
This publication has 50 references indexed in Scilit:
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NACJournal of Translational Medicine, 2013
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resectionJournal of Hepatology, 2011
- Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patientsJournal of Hepatology, 2010
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinomaJournal of Gastroenterology, 2009
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular CarcinomaAnnals of Surgery, 2008
- Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironmentCancer Cell, 2006
- Early and Late Recurrence After Liver Resection for Hepatocellular CarcinomaAnnals of Surgery, 2006